In the present communication we present eight human embryos, understood between the 16 and 30 mm., carrier of renal half fusion -kidney in horseshoe-. We carry out a descriptive study based on fifty embryos of these stadiums (Collection Jiménez Collado), in order to establish the different normodifferenciative stadiums, as well as the possible schedule in which the malformation settles down, for finally to suggest possible mechanism-hypothesis that explain the presence of the renal half fusion.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metabolically stable apelin analogs: development and functional role in water balance and cardiovascular function.
Clin Sci (Lond)
January 2025
Center for Interdisciplinary Research in Biology, College de France, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Apelin, a (neuro) vasoactive peptide, plays a prominent role in controlling water balance and cardiovascular functions. Apelin and its receptor co-localize with vasopressin in magnocellular vasopressinergic neurons. Apelin receptors (Apelin-Rs) are also expressed in the collecting ducts of the kidney, where vasopressin type 2 receptors are also present.
View Article and Find Full Text PDF.
IJID Reg
March 2025
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Objectives: To assess tuberculosis (TB) and associated factors among patients with presumptive TB with chronic kidney disease (CKD).
Methods: A prospective cross-sectional study was conducted from January to December 2023 among 381 patients with CKD attending six hospitals found in five regions of Ethiopia. Sputum and urine specimens were collected and examined for TB using smear microscopy, culture, and Xpert MTB/RIF Ultra assay.
Cotadutide reversible self-assembly based long-acting injectable depot for sustained delivery of GLP-1 glucagon receptor agonists with controlled burst release.
J Control Release
January 2025
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Waltham, MA, USA.
Cota is a lipidated dual GLP-1 and Glucagon receptor agonist that was investigated for the treatment of various metabolic diseases, it is designed for once daily subcutaneous administration. Invasive daily injections often result in poor patient compliance with chronic disease, and here, we demonstrate an innovative strategy of encapsulating reversible cota self-assembled fibers within an in-situ forming depot of low molecular weight poly(lactic-co-glycolic) acid (LWPLGA) for sustained delivery GLP-1 and Glucagon receptor agonist with controlled burst release. This could be a suitable alternative to other sustained delivery strategies for fibrillating peptides.
View Article and Find Full Text PDFSex differences in aristolochic acid I-induced nephrotoxicity in mice and the effect of estradiol.
Toxicol Appl Pharmacol
January 2025
School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China; Luzhou New Drug Evaluation and Research Center, Luzhou, Sichuan 646000, China. Electronic address:
Aristolochic acid I (AAI), the most prominent component of aristolochic acids and found in nearly all aristolochic herbs, has been demonstrated significant nephrotoxicity. In this study, an acute nephrotoxicity model of AAI mice was established by a single dose injection of AAI. It was observed that there are differences of the sensitivity to AAI nephrotoxicity in female and male mice, with male mice exhibiting nephrotoxic effects even at lower doses.
View Article and Find Full Text PDFCorticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials.
Hepatology
January 2025
Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA.
Background: Severe alcohol-associated hepatitis (AH) is rising in incidence with a high mortality burden. While corticosteroids are recommended for eligible patients with severe AH, no guidance exists for the timing of steroid initiation, tapering regimens, and surveillance of adverse events.
Objective: We aim to systematically review these variables and provide evidence-based recommendations for the inpatient and outpatient management of severe AH.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!